06.16.26 -- Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT

Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk.

Droplet digital PCR delivers the precise, low-copy quantification that standard qPCR cannot match. Discover why choosing deep analytical expertise ensures defensible data across tissues.

Manufacturing scale plays a critical role in viral vector economics. Compare AAV and LV production scenarios to gain insight into how intermediate-scale strategies can reduce cost and risk.

Delve into the dynamic transition towards automation in cell and gene therapy manufacturing as well as the challenges it presents to start ups with industry experts in this webinar.

Explore various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.

Engineered exosomes displaying tumor-homing peptides present a valuable vehicle for targeted cytotoxic drug delivery. Assess how bioreactors enable efficient output for critical research.

Learn how to navigate decision-making at critical steps and find solutions to key challenges in process development and scale-up to expedite oncolytic virus programs.

Traditional biomanufacturing relies too heavily on trial and error. By integrating AI and mechanistic models into early design, developers can overcome productivity limits and accelerate timelines.

A seven‑day CAR-T cell manufacturing workflow shows how cryopreserved leukapheresis material can deliver high viability and strong antitumor activity, offering a more flexible path for production.

Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.